Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18882644 | QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF | September 2024 | April 2025 | Allow | 8 | 1 | 1 | No | No |
| 18807584 | FORMULATIONS OF AMINOPENICILLIN AND METHODS FOR SOLUBILIZING AMINOPENICILLIN | August 2024 | May 2025 | Allow | 9 | 2 | 0 | Yes | No |
| 18723881 | SALT FORM AND CRYSTAL FORM OF TETRAHYDROCYCLOHEPTA INDAZOLE COMPOUND | August 2024 | May 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18832280 | BENZOISOTHIAZOLE AND BENZOISOXAZOLE COMPOUNDS FOR THE TREATMENT OF MENTAL DISORDERS | July 2024 | February 2025 | Allow | 7 | 0 | 0 | Yes | No |
| 18743025 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | June 2024 | March 2025 | Allow | 9 | 2 | 0 | No | No |
| 18420250 | METHOD OF TREATING ALZHEIMER�S DISEASE | January 2024 | October 2024 | Abandon | 9 | 1 | 0 | Yes | No |
| 18418030 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18408486 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18483401 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL | October 2023 | April 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18232651 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | August 2023 | April 2025 | Allow | 20 | 1 | 0 | No | No |
| 18366113 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | August 2023 | July 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18216089 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | June 2023 | May 2024 | Allow | 10 | 0 | 0 | Yes | No |
| 18331348 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | June 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18185711 | Anti-oxidant Compositions | March 2023 | August 2024 | Allow | 17 | 2 | 0 | Yes | No |
| 18173207 | LPXC INHIBITOR, FORMULATIONS, AND USES THEREOF | February 2023 | April 2024 | Abandon | 14 | 1 | 0 | No | No |
| 17985738 | COMBINATION TREATMENT OF LIVER DISORDERS | November 2022 | May 2025 | Abandon | 30 | 3 | 0 | No | No |
| 17979577 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | November 2022 | June 2023 | Allow | 8 | 1 | 0 | No | No |
| 18051654 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | November 2022 | July 2024 | Allow | 20 | 1 | 1 | No | No |
| 18050139 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | October 2022 | October 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17884933 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | August 2022 | September 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17874564 | PHARMACEUTICAL COMPOUNDS | July 2022 | December 2022 | Allow | 5 | 1 | 0 | No | No |
| 17872721 | METHODS FOR THE TREATMENT OF CANCER USING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | July 2022 | May 2025 | Allow | 34 | 3 | 1 | Yes | No |
| 17837851 | LIPID CRYSTALLINE COMPOSITIONS WITH ENHANCED STABILITY FOR TOPICAL DELIVERY OF ACTIVE AGENT COMBINATIONS | June 2022 | April 2025 | Abandon | 34 | 3 | 0 | Yes | No |
| 17664184 | METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS USING QUERCETIN-CONTAINING COMPOSITIONS | May 2022 | April 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17748451 | METHOD OF TREATING ALZHEIMER'S DISEASE | May 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17744537 | SOLID FORMS OF A MODULATOR OF HEMOGLOBIN | May 2022 | July 2023 | Allow | 15 | 1 | 0 | No | No |
| 17736908 | SHP2 INHIBITOR MONOTHERAPY AND USES THEREOF | May 2022 | April 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17733488 | EXPANDED DOSAGE REGIMENS FOR INTEGRIN INHIBITORS | April 2022 | May 2025 | Abandon | 37 | 4 | 0 | Yes | No |
| 17725398 | METHODS OF TREATING NON-HODGKIN LYMPHOMA USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | April 2022 | December 2024 | Abandon | 32 | 3 | 0 | No | No |
| 17720450 | PIPERIDINE UREA DERIVATIVES AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | April 2022 | January 2024 | Allow | 21 | 3 | 0 | Yes | No |
| 17713472 | Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer | April 2022 | August 2024 | Allow | 28 | 2 | 1 | Yes | No |
| 17713598 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS | April 2022 | April 2023 | Allow | 13 | 0 | 1 | No | No |
| 17690663 | CHEWABLE FORMULATIONS | March 2022 | November 2023 | Abandon | 20 | 1 | 1 | No | No |
| 17690094 | Orally Active Melanocortin Receptor-4 Compounds | March 2022 | June 2025 | Allow | 39 | 3 | 0 | Yes | No |
| 17687525 | TREATMENT OF COPPER DISORDERS | March 2022 | September 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17677437 | PARENTERAL COMPOSITIONS COMPRISING METHYLENE BLUE | February 2022 | November 2024 | Allow | 33 | 4 | 0 | Yes | No |
| 17677408 | SOLUTION FORMULATIONS OF CX-011 | February 2022 | January 2024 | Allow | 22 | 2 | 1 | No | No |
| 17672670 | EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESS | February 2022 | March 2025 | Abandon | 37 | 6 | 0 | Yes | No |
| 17671714 | DOSAGE REGIMENS FOR PARP7 INHIBITORS | February 2022 | October 2023 | Abandon | 20 | 1 | 0 | No | No |
| 17670712 | ABIRATERONE PRODRUGS | February 2022 | January 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17649938 | CANNABINOID FORMULATION: PRODUCTION METHOD AND USE | February 2022 | October 2023 | Allow | 20 | 1 | 0 | No | No |
| 17549227 | METHODS FOR TREATING CILIATED CAVITIES | December 2021 | February 2023 | Allow | 14 | 0 | 0 | No | No |
| 17534771 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | November 2021 | May 2024 | Abandon | 29 | 2 | 0 | No | No |
| 17533931 | METHODS OF SYNTHESIZING SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | November 2021 | May 2023 | Allow | 17 | 1 | 0 | No | No |
| 17515758 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | November 2021 | March 2025 | Abandon | 41 | 1 | 1 | No | No |
| 17451462 | BICYCLIC COMPOUNDS | October 2021 | December 2023 | Allow | 26 | 2 | 0 | No | No |
| 17438413 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17458797 | THIENOPYRIMIDINONE NMDA RECEPTOR MODULATORS AND USES THEREOF | August 2021 | January 2023 | Allow | 16 | 0 | 0 | No | No |
| 17406771 | AQUEOUS, ROOM-TEMPERATURE STABLE ROCURONIUM COMPOSITION | August 2021 | March 2024 | Abandon | 31 | 2 | 1 | No | No |
| 17443699 | LAURETH-4 CONTAINING TOPICAL FORMULATIONS | July 2021 | May 2023 | Allow | 22 | 2 | 0 | Yes | No |
| 17300457 | Formulations and methods | July 2021 | January 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17360781 | TREATMENT OF FRAGILE X SYNDROME WITH CANNABIDIOL | June 2021 | December 2023 | Abandon | 30 | 2 | 0 | No | No |
| 17311560 | Crystalline Forms of 1-[(3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-Fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide | June 2021 | February 2024 | Allow | 33 | 0 | 0 | Yes | No |
| 17339415 | PHARMACEUTICAL COMPOSITIONS FOR INTRAVENOUS INFUSION IN PLASTIC BAGS WITH REDUCED ADSORPTION ON BAG MEMBRANE | June 2021 | June 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17336059 | MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE | June 2021 | March 2024 | Allow | 33 | 1 | 1 | No | No |
| 17294860 | AQUEOUS SOLUTIONS OF POORLY SOLUBLE ACTIVE INGREDIENTS USING POLYALKYOXYLATED AMINO ALCOHOLS | May 2021 | March 2025 | Allow | 46 | 2 | 1 | No | Yes |
| 17293970 | LOX INHIBITORS | May 2021 | June 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17313679 | METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME | May 2021 | July 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17306005 | CO-CRYSTALS OF SODIUM BENZOATE AND USES THEREOF | May 2021 | March 2023 | Allow | 23 | 1 | 0 | No | No |
| 17243706 | TABLET CONTAINING ANTITUMOR AGENT | April 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17242185 | Therapeutic Thiazine Dye Compositions and Methods of Use | April 2021 | October 2024 | Abandon | 42 | 2 | 1 | No | Yes |
| 17287907 | CRYSTALLINE FORMS OF POTASSIUM CHANNEL MODULATORS | April 2021 | January 2024 | Allow | 33 | 0 | 0 | Yes | No |
| 17223507 | METHODS AND COMPOSITIONS FOR INHIBITING MUSCLE WASTING | April 2021 | June 2023 | Abandon | 26 | 1 | 1 | No | No |
| 17280620 | INFIGRATINIB FOR TREATMENT OF FGFR3-RELATED SKELETAL DISEASES DURING PREGNANCY | March 2021 | April 2024 | Abandon | 36 | 3 | 0 | Yes | No |
| 17210899 | METHODS OF TREATING A SUBJECT HAVING AN INFECTIOUS DISEASE | March 2021 | May 2023 | Abandon | 25 | 0 | 1 | No | No |
| 17211025 | LPXC INHIBITOR, FORMULATIONS, AND USES THEREOF | March 2021 | April 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17208043 | ETORICOXIB SOLVATES AND PREPARATION METHOD THEREOF | March 2021 | March 2023 | Allow | 24 | 1 | 1 | No | No |
| 17277475 | COMBINATIONS OF TGF-BETA INHIBITORS AND CDK INHIBITORS FOR CANCER TREATMENTS | March 2021 | June 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17275555 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NONALCOHOLIC FATTY LIVER DISEASE, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENT | March 2021 | August 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17275176 | COMBINATION THERAPIES | March 2021 | September 2024 | Allow | 42 | 3 | 0 | Yes | No |
| 17275178 | COMBINATION THERAPIES | March 2021 | September 2024 | Allow | 43 | 3 | 0 | Yes | No |
| 17180593 | METHODS OF USE OF EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST | February 2021 | September 2023 | Allow | 31 | 1 | 0 | No | No |
| 17269569 | Arginase Inhibitors and Methods of Use thereof | February 2021 | December 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17269244 | ADAMANTANYL-SUBSTITUTED BENZAMIDE COMPOUNDS AND THEIR USE AS P2X7 RECEPTOR ANTAGONISTS | February 2021 | May 2024 | Abandon | 39 | 3 | 0 | No | No |
| 17268049 | COMBINATION THERAPY | February 2021 | October 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17266433 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | February 2021 | August 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 17168158 | BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF | February 2021 | July 2024 | Allow | 41 | 1 | 0 | No | No |
| 17264882 | SUBSTITUTED BENZAMIDES AND THEIR USE IN THERAPY | February 2021 | May 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17262586 | NOVEL TRICYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | January 2021 | January 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17262170 | PIPERAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | January 2021 | December 2023 | Allow | 34 | 0 | 0 | Yes | No |
| 17260592 | NOVEL COMPOUND ISOLATED FROM CERVI PARVUM CORNU, AND PHARMACEUTICAL USES THEREOF | January 2021 | March 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17149901 | CONVERGENT SYNTHESIS OF POZIOTINIB DERIVATIVE | January 2021 | June 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17149244 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | January 2021 | February 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17260188 | METHODS OF TREATING RENAL DISEASE | January 2021 | June 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17258913 | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | January 2021 | October 2024 | Allow | 45 | 3 | 0 | Yes | No |
| 17257738 | PROCESS FOR THE PRODUCTION OF ARYLAMINES | January 2021 | August 2024 | Abandon | 44 | 2 | 0 | No | No |
| 17138214 | METHODS OF TREATING AND PREVENTING NEURODEGENERATIVE DISEASES WITH HGF ACTIVATING COMPOUNDS | December 2020 | September 2024 | Abandon | 45 | 3 | 1 | No | No |
| 17120040 | SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS | December 2020 | October 2022 | Allow | 22 | 1 | 0 | No | No |
| 17251621 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | December 2020 | March 2025 | Abandon | 51 | 3 | 1 | No | No |
| 17058982 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | November 2020 | November 2022 | Allow | 24 | 1 | 0 | No | No |
| 17054706 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | November 2020 | January 2025 | Allow | 50 | 4 | 1 | Yes | No |
| 17088718 | 9-Aminomethyl Minocycline Compounds And Use Thereof In Treating Community-Acquired Bacterial Pneumonia (CABP) | November 2020 | March 2024 | Abandon | 41 | 1 | 0 | No | No |
| 16974157 | EYE DROPS WITH CITRIC ACID AS THE SOLE ACTIVE INGREDIENT | October 2020 | December 2023 | Abandon | 37 | 5 | 0 | No | No |
| 17047992 | TUMOR ABLATION USING LOW-INTENSITY ULTRASOUND AND SOUND EXCITABLE DRUG | October 2020 | January 2024 | Allow | 39 | 1 | 0 | No | No |
| 17047132 | CHLOROQUINE-BASED MATERIALS FOR THE TREATMENT OF DISEASES | October 2020 | May 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17035611 | METHODS OF USE OF CYCLOPAMINE ANALOGS | September 2020 | October 2022 | Allow | 25 | 1 | 0 | No | No |
| 17040159 | PIPERIDINE COMPOUNDS AS COVALENT MENIN INHIBITORS | September 2020 | October 2023 | Abandon | 37 | 1 | 0 | No | No |
| 17024799 | MEANS TO FACILITATE FOOD INTAKE AND FOOD RETENTION | September 2020 | November 2023 | Allow | 38 | 2 | 0 | No | No |
| 16982517 | COMPOUND WHICH INHIBITS TELOMERE-BINDING PROTEIN, AND TELOMERE-BINDING PROTEIN INHIBITOR CONTAINING SAME | September 2020 | August 2023 | Allow | 35 | 0 | 0 | No | No |
| 16931128 | TREATMENT OF IRRITABLE BOWEL AND INFLAMMATORY BOWEL DISEASE | July 2020 | March 2024 | Abandon | 44 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ABDALHAMEED, MANAHIL MIRGHANI ALI.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 25.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ABDALHAMEED, MANAHIL MIRGHANI ALI works in Art Unit 1622 and has examined 99 patent applications in our dataset. With an allowance rate of 53.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner ABDALHAMEED, MANAHIL MIRGHANI ALI's allowance rate of 53.5% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI receive 1.73 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +41.0% benefit to allowance rate for applications examined by ABDALHAMEED, MANAHIL MIRGHANI ALI. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.3% of applications are subsequently allowed. This success rate is in the 33% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 49% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 57.1% are granted (fully or in part). This grant rate is in the 72% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.